Why the study?
This mini-review was conducted to explore emerging predictors and novel biomarkers associated with coronary slow flow to address potential diagnostic tools.
What are the emerging predictors and novel biomarkers associated with the coronary slow flow phenomenon?
What are the emerging predictors and novel biomarkers associated with the coronary slow flow phenomenon?
Emerging biomarkers and lipid ratios may serve as novel diagnostic tools to predict coronary slow-flow phenomenon and guide personalized treatment strategies.
Emerging CSF biomarkers show diagnostic promise; leaves open prospective validation before clinical use.
The coronary slow-flow (CSF) phenomenon is a condition characterized by delayed coronary opacification during diagnostic angiography without the presence of epicardial coronary artery disease. This mini-review explores various emerging predictors and biomarkers associated with CSF, aiming to address the potential diagnostic tools. A comprehensive analysis of recent studies has investigated different biomarkers, including growth differentiation factor 15, galectin 3, microRNA (miRNA)-22, miRNA-155, interleukin 34, soluble vascular cell adhesion molecule-1, long non-coding RNA, plasma choline, adropin, and lipid markers non-high-density lipoprotein cholesterol (HDL-C)/HDL-C ratio to enhance understanding and predict CSF. Additionally, we have summarizes the major findings and significant limitations observed in various studies on CSF biomarkers. The implications of these findings suggest significant advancements in personalized treatment strategies and improved prognostic outcomes for patients exhibiting CSF.
No takes yet. Share an insight, caveat, or question.
Vairaperumal et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: